The Scleroderma Biorepository and Pathogenesis Study (STOP Scleroderma)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02887495

Enrollment

600

Registered

2016-09-02

Start date

2014-07-31

Completion date

2022-02-02

Last updated

2022-07-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Scleroderma

Keywords

scleroderma, biorepository

Brief summary

The Scleroderma bioreposiTOry and Pathogenesis Study (STOP Scleroderma) will help researchers use clinical data and human biospecimens to investigate why scleroderma patients develop certain complications from their disease. Patients with confirmed scleroderma, raynauds or positive autoantibodies are invited to participate. This research may help us understand how to prevent and treat scleroderma and other diseases.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 100 Years

Healthy volunteers

Inclusion criteria

* Age \>18 years * Able to give informed consent. * Diagnosed with scleroderma or with positive autoantibodies

Exclusion criteria

* \< 18 years old

Design outcomes

Primary

Measure	Time frame
Modified Rodnan Skin Score	10 years

Secondary

Measure	Time frame
Medsger Severity Score	10 years

Countries

United States

Outcome results